sensiblex 40 mg/ml solution for injection for cattle
veyx-pharma gmbh - denaverine hydrochloride - solution for injection - 40.0 milligram(s)/millilitre - denaverine - cattle - miscellaneous
sensiblex 40 mg/ml solution for injection for cattle
veyx-pharma gmbh - denaverine hydrochloride - solution for injection - neurological agent uterine relaxant - cattle
sensiblex 40 mg/ml injektionslösung für rinder
rescriptor delavirdine mesylate tablet
kaiser foundation hospitals - delavirdine mesylate (unii: 421105krqe) (delavirdine - unii:dol5f9jd3e) - delavirdine mesylate 200 mg
rescriptor- delavirdine mesylate tablet
viiv healthcare company - delavirdine mesylate (unii: 421105krqe) (delavirdine - unii:dol5f9jd3e) - delavirdine mesylate 100 mg - rescriptor tablets are indicated for the treatment of hiv-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. the following should be considered before initiating therapy with rescriptor in treatment-naive patients. there are insufficient data directly comparing antiretroviral regimens containing rescriptor with currently preferred 3-drug regimens for initial treatment of hiv. in studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (nrtis) (currently considered suboptimal) to rescriptor plus 2 nrtis, the proportion of patients receiving the regimen containing rescriptor who achieved and sustained an hiv-1 rna level <400 copies/ml over 1 year of therapy was relatively low (see description of clinical studies). resistant virus emerges rapidly when rescriptor is administered as monotherapy. therefore, rescriptor should always be administered in combination with other antiretroviral agents. rescriptor tablets are contraindicate
rescriptor tablet
viiv healthcare ulc - delavirdine mesylate - tablet - 100mg - delavirdine mesylate 100mg - nonnucleoside reverse transcriptase inhibitors
spasmopriv forte capsules
laboratorios legrand s.a. - fenoverine - capsules - 200mg
rescriptor
glaxosmithkline nz limited - delavirdine mesilate 100mg equivalent to 82.6 mg delavirdine base; - film coated tablet - 100 mg - active: delavirdine mesilate 100mg equivalent to 82.6 mg delavirdine base excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7000e
nicotrol
johnson & johnson (new zealand) limited - nicotine 8.3mg (as a 10cm² patch delivering 5mg/16hours); - transdermal patch - 0.31 mg/h - active: nicotine 8.3mg (as a 10cm² patch delivering 5mg/16hours)
nicotrol
johnson & johnson (new zealand) limited - nicotine 16.6mg (as a 20cm² patch delivering 10mg/16hours); - transdermal patch - 0.62 mg/h - active: nicotine 16.6mg (as a 20cm² patch delivering 10mg/16hours)